- Home
- LBRDK vs RLAY Comparison
LBRDK vs RLAY Comparison
Compare LBRDK & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRDK | RLAY |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LBRDK | RLAY |
|---|---|---|
| Price | $36.77 | $19.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.91 | ★ 31.78 |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $22,256,000.00 | $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $109.28 | $324.03 |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | ★ 70.00 | 53.44 |
| 52 Week Low | $26.25 | $3.52 |
| 52 Week High | $65.73 | $21.27 |
Technical Indicators
Market Signals| Indicator | LBRDK | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 49.53 |
| Support Level | $29.37 | $18.02 |
| Resistance Level | $39.60 | $20.82 |
| Average True Range (ATR) | 1.62 | 0.92 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 71.46 | 33.76 |
Price Performance
Historical ComparisonAbout LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.